Related Experiment Video
Updated: May 21, 2025

Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
Published on: May 26, 2023
Perioperative anaphylaxis in children and first successful cisatracurium desensitization
Sophie H Y Lai1,2, Rowena S M Lee3, Crystal K Lam4
1Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China.
Insights
Perioperative anaphylaxis in children is often caused by neuromuscular blocking agents (NMBAs) and beta-lactam antibiotics. Skin testing effectively identifies culprits, and successful desensitization to cisatracurium was achieved.
Area of Science:
- Anesthesiology
- Pediatric Allergy and Immunology
- Clinical Pharmacology
Background:
- Perioperative anaphylaxis (PA) is a rare but severe complication of anesthesia in children.
- Diagnosing PA and identifying causative agents is challenging due to limited drug provocation testing (DPT).
- Desensitization protocols for pediatric PA are not previously reported.
Purpose of the Study:
- To evaluate diagnostic testing for pediatric PA.
- To identify common causative agents in pediatric PA.
- To report the first successful desensitization to cisatracurium in a pediatric patient.
Main Methods:
- Retrospective review of medical records for pediatric patients (≤18 years) with PA (2019-2024).
- Analysis of serum tryptase levels, skin testing (ST), and basophil activation testing (BAT).
- Detailed description of the desensitization protocol for cisatracurium.
Main Results:
- Neuromuscular blocking agents (NMBAs) (70%) and beta-lactam antibiotics (20%) were the most frequent culprits.
- Skin testing (ST) identified the culprit in 90% of cases.
- Successful desensitization to cisatracurium was achieved in one patient with limited drug options.
Conclusions:
- NMBAs are the primary cause of PA in children, identified effectively by ST.
- Serum tryptase levels correlate with PA, and BAT serves as an adjunct diagnostic tool.
- Desensitization to cisatracurium is a viable option for pediatric patients with limited treatment alternatives.
Background:
Perioperative anaphylaxis (PA) is a rare life-threatening complication of anesthesia, with few descriptions of its diagnosis and outcomes in the pediatric population. Many agents can be potential culprits, and drug provocation testing (DPT) to confirm the diagnosis is limited by the nature of anesthetic drugs. PA diagnosis and culprit identification remain a challenge. For patients with limited drug options, desensitization has not been reported. This study evaluated the results of skin and laboratory testing for pediatric patients with PA and provides the protocol and outcome of the first desensitization to cisatracurium, a neuromuscular blocking agent (NMBA).
Methods:
Patients ≤18 years old with PA from 2019 to 2024 were included, and medical records were retrospectively reviewed, which comprised serum tryptase levels, results of skin testing (ST), basophil activation testing (BAT), and outcomes.
Results:
Eleven patients were included. Tryptase was elevated in seven of 10 (70%) tested patients. ST yielded positive results for nine of 10 (90%), and two of 11 (18.2%) had positive BAT.
Results:
A culprit agent was identified in 10 of 11 (91%). The most common drugs were NMBAs (70%) and beta-lactam antibiotics (20%). One patient with a positive DPT to NMBAs and limited alternatives was successfully desensitized to cisatracurium with a 3-bag, 12-step protocol.
Conclusion:
The most common drug culprits of PA in children were NMBAs and were identified by ST. Tryptase correlated with PA. BAT served as adjunctive diagnostic tests. Desensitization to cisatracurium was possible.
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Allergic Reactions
Parenteral Anesthetics: Overview
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Skeletal Muscle Relaxants: Therapeutic Uses

